Clinical Trial

ENX-205 SAD/PET Study in Healthy Adults

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a two-part study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and receptor occupancy (RO) of ENX-205 in healthy adult participants in a double-blind placebo-controlled, single ascending dose (SAD) study (Part 1) and an open-label, single-dose, positron emission tomography (PET) study (Part 2).
Protocol Amendment History 3 changes
critical Trial completed 2026-05-29
notable Primary completion pushed: 2026-04 -> 2026-05-07 2026-05-29
minor Completion pushed: 2026-04 -> 2026-05-07 2026-05-29
Trial Details
NCT Number NCT07253246
Lead Sponsor Engrail Therapeutics INC
Conditions Healthy Volunteer
Enrollment 59 participants
Start Date 2025-03-23
Primary Completion 2026-05-07 (estimated)
Study Completion 2026-05-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-28